Disclosed herein are new therapeutic methods and compositions for maintaining and regenerating intestinal epithelial cells in a mammal. In a specific embodiment, the methods involve administering an amount LIF that induces intestinal epithelial cell regeneration. The methods and compositions are useful for preventing or treating gastrointestinal radiation injury or GVHD.

Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.

Disclosed are a pharmaceutical composition for treatment of endometrium damage, a composition for enhancing implantation ability, and a pharmaceutical composition for prevention or treatment of infertility or subfertility. The pharmaceutical composition for treatment of endometrium damage includes decidual endometrial stromal cells and hyaluronic acid, the composition for enhancing implantation ability includes decidual endometrial stromal cells and hyaluronic acid, and the pharmaceutical composition for prevention or treatment of infertility or subfertility includes decidual endometrial stromal cells and hyaluronic acid.

The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.

The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.

A pharmaceutical composition is provided comprising a first agent in an amount effective for causing both a peripheral effect and a central effect on weight loss, a second agent in an amount effective for causing at least a central effect on weight loss, and one or more pharmaceutically acceptable excipients, wherein the first agent and the second agent are different. Also provided are a method of causing weight loss and a method of preventing or treating cachexia syndrome.

A pharmaceutical composition is provided comprising a first agent in an amount effective for causing both a peripheral effect and a central effect on weight loss, a second agent in an amount effective for causing at least a central effect on weight loss, and one or more pharmaceutically acceptable excipients, wherein the first agent and the second agent are different. Also provided are a method of causing weight loss and a method of preventing or treating cachexia syndrome.

Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.

There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of: brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.

There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of: brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.